• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Treat NMD Logo (Copyright)

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us

Congenital muscular dystrophy

Home / Resources and Support / Neuromuscular Disease Information / Congenital muscular dystrophy

What is congenital muscular dystrophy?

Congenital muscular dystrophy (CMD) does not just encompass one disease but a group of inherited neuromuscular conditions that usually display symptoms at birth or in early infancy. All congenital muscular dystrophies affect the muscles, but a few also affect the brain resulting in both muscle weakness and cognitive impairment. There are many subtypes of CMD including: Collagen 6-CMD (Bethlem, Intermediate and Ullrich), LAMA2-CMD, alpha-Dystroglycanopathies (WWS, MEB, Fukuyama, LGMD), SELENON-related myopathy and LMNA-CMD.

What causes congenital muscular dystrophy?

CMDs are caused by genetic mutations that affect important muscle proteins. Most forms of CMD are inherited in an autosomal recessive pattern which means that two copies of the mutated gene are required to result in the disease. However, dominant cases, mostly derived from the novo mutations with dominant-negative effect are also observed.

Many CMDs are caused by mutations that affect proteins that form a key part of the complex scaffolding – called the extracellular matrix (ECM) – that supports the cells of our body including muscle.  The loss of these types of proteins e.g. glycoproteins, (or the enzymes that create them) as well as Collagen 6 and LAMA2 can interfere with normal muscle function, but it is still unclear why CMDs cause muscle weakness earlier than other types of muscular dystrophy.

What are the signs and symptoms of congenital muscular dystrophy?

As people with CMDs usually display symptoms from birth or early infancy, a child may display muscle weakness (usually identified as hypotonia) or a lack of muscle tone which may make an infant seem ‘floppy’. Infants and toddlers may then have difficulty meeting motor milestones such as rolling, sitting, or walking.

Some of the subtypes of CMD may be accompanied by cognitive impairment, visual impairments (in MEB for example), and seizures as the function of the brain can be affected. These complications are usually evident in the first year of life, and severity is variable. Sooner or later, most forms of CMD will present breathing and feeding issues as well as joint and spinal contractures due to an increase in muscle weakness.

How does the disease progress?

The severity of CMDs varies significantly from one person to another and from one subtype to another, therefore, it is important to focus on care that allows patients to achieve goals within their capability.

Some children will be able to walk, although this may be delayed, and those who are able to walk may not be able to later in life due to growth and the dystrophic (progressive) nature of the condition.

For more specific information on all CMD subtypes, please visit the Cure CMD webpage.

 

Primary Sidebar

  • Resources and Support
  • Disease Information
    • Neuromuscular Disease Information
    • Becker muscular dystrophy
    • Charcot-Marie-Tooth
    • Congenital muscular dystrophy
    • Congenital myasthenic syndromes
    • Duchenne muscular dystrophy
    • Facioscapulohumeral muscular dystrophy
    • GNE myopathy
    • Limb girdle muscular dystrophy
    • Myotonic dystrophy
    • Myotubular and centronuclear myopathies
    • Spinal muscular atrophy
  • Research Overview
    • Research Overview
    • Gene Therapy Research
    • DMD
      • DMD
      • Gene Therapy for DMD
      • Mutation Specific Approaches
      • Drug Therapy
        • Anti Inflammatory Drugs
        • Treating Fibrosis and Oxidative Stress
        • Ways to Improve Muscle Quality and Strenghth
        • Drugs to Bloodflow to Muscle
        • Drugs to Upregulate Utrophin
      • Cell Therapy
  • Standards of Care & Family Guides
    • Care Guides
    • BMD Care
    • CM Care
    • CMD Care
    • DM Care
    • DMD Care
    • FSHD Care
    • LGMD Care
    • SMA Care
  • Standard Operating Procedures (SOPs)
    • SOP Library
    • MDX Mouse (DMD)
    • GRMD Dog (DMD)
    • CMD Mouse (CMD)
    • SMA Mouse (SMA)
    • SOP Archive
      • MDX mouse (DMD) Archive
      • SMA mouse (SMA) Archive
      • Mouse model (DMD) Archive
  • Social and Ethical issues
    • Social and Ethical Issues
    • Concerns Over Stem Cell Therapy for SMA Type 1 Children
    • Early Access to Medicines in Development
    • Ethical Questions

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

 
ISO 27001 Accreditation Logo

Connect

info@treat-nmd.com
TREAT NMD © 2025
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
    • The Global Registry Network
      • Members of the Registry Network
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
    • Education
      • Masterclasses and Events
      • Digital Resources
      • Endorsement of External Programmes
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • BMD Care
      • FSHD Care
      • SMA Care
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us